-

Johnson & Johnson Names Eugene A. Woods, Chief Executive Officer of Advocate Health, to its Board of Directors

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) announced today that Eugene A. Woods, MBA, MHA, Chief Executive Officer of Advocate Health, has been appointed to its Board of Directors.

“Mr. Woods is an exceptional addition to Johnson & Johnson’s Board of Directors,” said Joaquin Duato, Chairman and Chief Executive Officer, Johnson & Johnson. “Mr. Woods has an impressive career of leading and transforming healthcare systems while prioritizing the delivery of high-quality, equitable patient care. The Board looks forward to working with him as the Company continues to focus on healthcare innovation and tackling the toughest health challenges.”

“It is an honor to join the Johnson & Johnson Board of Directors as they work to reimagine healthcare through transformative innovation,” said Mr. Woods. “I have dedicated my career to advancing equitable and affordable healthcare for all, and I look forward to serving alongside board members who are equally passionate about serving patients and improving health outcomes.”

About Eugene A. Woods, MBA, MHA

Mr. Woods is a prominent leader in healthcare with more than three decades of experience in leading and operating hospitals, health systems, and healthcare organizations across the country. Currently, he is the Chief Executive Officer of Advocate Health headquartered in Charlotte, North Carolina. In this role, he leads one of the largest non-profit health systems in the country—providing care to more than six million patients across 68 hospitals and over 1,000 care locations. Mr. Woods has held several leadership roles in his distinguished career, including President and CEO of Atrium Health and President and Chief Operating Officer of CHRISTUS Health. In each position, he has prioritized positive health outcomes and equitable care for all patients.

Mr. Woods is the incoming chair of the Charlotte Executive Leadership Council and is a member of the Healthcare Institute, Becker’s Healthcare Advisory Board, the board of Best Buy, and the board of Johnson C. Smith University. He is also a Fellow of the American College of Healthcare Executives. Mr. Woods attended Pennsylvania State University, where he earned a bachelor’s degree and two master’s degrees.

The full Board of Directors list is available on the Johnson & Johnson website at https://www.jnj.com/leadership/our-leadership-team#board-of-directors.

About Johnson & Johnson

At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity. Learn more at https://www.jnj.com/.

Contacts

Media contact:
Tesia Williams
media-relations@its.jnj.com

Investor contact:
Jessica Moore
investor-relations@its.jnj.com

Johnson & Johnson

NYSE:JNJ

Release Versions

Contacts

Media contact:
Tesia Williams
media-relations@its.jnj.com

Investor contact:
Jessica Moore
investor-relations@its.jnj.com

More News From Johnson & Johnson

Johnson & Johnson Invests more than $1 Billion to Strengthen U.S. Vision Manufacturing in Jacksonville, Florida

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) (the “Company”), healthcare’s leading, most comprehensive innovation powerhouse, today announced an investment of more than $1 billion in Jacksonville, Florida to strengthen its Vision operations by scaling U.S.-based manufacturing, packaging and distribution capabilities. The investment includes construction of a new, state-of-the-art distribution facility, alongside advanced manufacturing and packaging technologies to exp...

Johnson & Johnson to Acquire Firefly Bio, Inc. to Expand Oncology Pipeline with Novel Degrader Antibody Conjugate Platform

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) today announced it has entered into a definitive agreement to acquire Firefly Bio, Inc., a biotechnology company advancing its proprietary Firelink™ degrader antibody conjugate (DAC) platform, for $1 billion in cash. The Firelink™ DAC platform for KRAS-driven tumors bolsters Johnson & Johnson’s oncology pipeline and ambition to develop targeted medicines for the most prevalent and hard-to-treat solid tumors with high un...

Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Wednesday, July 15th to review second-quarter results. Joaquin Duato, Chairman and Chief Executive Officer, Joseph J. Wolk, Executive Vice President and Chief Financial Officer and Ryan Koors, Vice President, Investor Relations will host the call. The question and answer portion of the call will also include additional members of Johnson & Johnson’...
Back to Newsroom